Moderna Announces its COVID-19 Vaccine Phase 2/3 Study in Children 6 Months to Under 6 Years Has Successfully Met Its Primary Endpoint
Moderna data on 25 microgram dose 28 days apart of mRNA vaccine for children 6 months-just under 6 years old. Good news is that immunogenicity adequate across age range as measured by neutralizing antibodies (same as >18). Vaccine efficacy lower than expected (<50%) with Omicron but that was against mild disease (no severe disease in Moderna or placebo arm) – would be good for company to measure B/T cells in subset but likely generated well
